Parallel evolution of circulating FABP4 and NT-proBNP in heart failure patients
| Autor: | Iolanda Lázaro, Alfredo Bardají, Gil Bonet, Pilar Valdovinos, Lluís Masana, Anna Cabré |
|---|---|
| Přispěvatelé: | Medicina i Cirurgia, Universitat Rovira i Virgili. |
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty medicine.drug_class Endocrinology Diabetes and Metabolism FABP4 Fatty Acid-Binding Proteins Insulin resistance Internal medicine Diabetes mellitus Heart rate Natriuretic Peptide Brain Natriuretic peptide Medicine Humans Longitudinal Studies Prospective Studies Obesity Prospective cohort study Angiology Aged Original Investigation Heart Failure business.industry Diabetes Case-control study Middle Aged medicine.disease Peptide Fragments Infart de miocardi Cross-Sectional Studies NT-proBNP Heart failure Case-Control Studies Cardiology Disease Progression Female business Cardiology and Cardiovascular Medicine Biomarkers |
| Zdroj: | Cardiovascular Diabetology Repositori Institucional de la Universitat Rovira i Virgili Universitat Rovira i virgili (URV) |
| ISSN: | 1475-2840 |
| DOI: | 10.1186/1475-2840-12-72 |
| Popis: | Background Circulating adipocyte fatty acid-binding protein (FABP4) levels are considered to be a link between obesity, insulin resistance, diabetes, and cardiovascular (CV) diseases. In vitro, FABP4 has exhibited cardiodepressant activity by suppressing cardiomyocyte contraction. We have explored the relationship between FABP4 and the N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP) as a clinical parameter of heart failure (HF). Methods We included 179 stable HF patients who were referred to a specialized HF unit, 108 of whom were prospectively followed for up to 6 months. A group of 163 non-HF patients attending a CV risk unit was used as the non-HF control group for the FABP4 comparisons. Results In the HF patients, FABP4 and NT-proBNP were assayed, along with a clinical and functional assessment of the heart at baseline and after 6 months of specialized monitoring. The FABP4 levels were higher in the patients with HF than in the non-HF high CV risk control group (pp Conclusions FABP4 is associated with the clinical manifestations and biomarkers of HF. It exhibits a parallel evolution with the circulating levels of NT-proBNP in HF patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink